DaxibotulinumtoxinA

DRUG4 trials

Sponsors

Revance Therapeutics, Inc., University of California, San Francisco, Ki Health Partners. LLC, Montefiore Medical Center

Conditions

Adductor Spasmodic DysphoniaBenign Essential BlepharospasmHemifacial SpasmMigraine DisordersSpasmodic DysphoniaTorticollis (Spasmodic)Voice Disorders

Phase 1

DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia

CompletedNCT05158166

University of California, San FranciscoAdductor Spasmodic Dysphonia, Spasmodic Dysphonia, Voice Disorders

Start: 2023-10-13End: 2025-03-02Updated: 2026-05-18

Phase 2

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

CompletedNCT02706795

Revance Therapeutics, Inc.Torticollis (Spasmodic)

Start: 2015-09-30End: 2017-07-17Updated: 2019-11-06

Phase 4

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

RecruitingNCT06195241

Montefiore Medical CenterBenign Essential Blepharospasm, Hemifacial Spasm

Start: 2025-02-11End: 2027-03-01Target: 40Updated: 2026-04-23

Unknown Phase

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

Active, not recruitingNCT06154070

Ki Health Partners. LLCMigraine Disorders

Start: 2023-10-24End: 2024-10-31Target: 10Updated: 2024-05-10

Related Papers

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study.

2018-04-2634 citations